ICPT Annual EBITDA
-$153.47 M
-$116.90 M-319.63%
31 December 2022
Summary:
As of February 5, 2025, ICPT annual earnings before interest, taxes, depreciation & amortization is -$153.47 million, with the most recent change of -$116.90 million (-319.63%) on December 31, 2022. During the last 3 years, it has risen by +$148.53 million (+49.18%).ICPT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ICPT Quarterly EBITDA
-$1.11 M
+$2.18 M+66.19%
30 September 2023
Summary:
As of February 5, 2025, ICPT quarterly earnings before interest, taxes, depreciation & amortization is -$1.11 million, with the most recent change of +$2.18 million (+66.19%) on September 30, 2023. Over the past year, it has increased by +$98.30 million (+98.88%).ICPT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ICPT TTM EBITDA
-$47.85 M
+$98.30 M+67.26%
30 September 2023
Summary:
As of February 5, 2025, ICPT TTM earnings before interest, taxes, depreciation & amortization is -$47.85 million, with the most recent change of +$98.30 million (+67.26%) on September 30, 2023. Over the past year, it has increased by +$121.76 million (+71.79%).ICPT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ICPT EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -319.6% | +98.9% | +71.8% |
| 3 y3 years | +49.2% | +98.0% | +82.5% |
| 5 y5 years | +53.0% | +98.0% | +84.2% |
ICPT EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +1043.6% | -103.3% | +1569.5% |
Intercept Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$1.11 M(-66.2%) | -$47.85 M(-67.3%) |
| June 2023 | - | -$3.29 M(-88.6%) | -$146.15 M(-7.1%) |
| Mar 2023 | - | -$28.98 M(+100.5%) | -$157.24 M(+1.7%) |
| Dec 2022 | -$153.47 M(+319.6%) | -$14.46 M(-85.5%) | -$154.68 M(-8.8%) |
| Sept 2022 | - | -$99.41 M(+591.0%) | -$169.60 M(+132.6%) |
| June 2022 | - | -$14.39 M(-45.6%) | -$72.91 M(+2.5%) |
| Mar 2022 | - | -$26.42 M(-10.1%) | -$71.16 M(-1.0%) |
| Dec 2021 | -$36.57 M(-83.8%) | -$29.39 M(+984.0%) | -$71.87 M(-11.2%) |
| Sept 2021 | - | -$2.71 M(-78.6%) | -$80.89 M(-38.9%) |
| June 2021 | - | -$12.64 M(-53.4%) | -$132.49 M(-22.5%) |
| Mar 2021 | - | -$27.13 M(-29.4%) | -$171.02 M(-23.8%) |
| Dec 2020 | -$226.25 M(-25.1%) | -$38.41 M(-29.3%) | -$224.33 M(-18.1%) |
| Sept 2020 | - | -$54.31 M(+6.1%) | -$273.76 M(-6.1%) |
| June 2020 | - | -$51.17 M(-36.4%) | -$291.57 M(-3.1%) |
| Mar 2020 | - | -$80.44 M(-8.4%) | -$301.01 M(-0.3%) |
| Dec 2019 | -$302.00 M(+10.2%) | -$87.84 M(+21.8%) | -$302.00 M(+2.9%) |
| Sept 2019 | - | -$72.12 M(+19.0%) | -$293.39 M(+5.9%) |
| June 2019 | - | -$60.61 M(-25.6%) | -$276.92 M(-2.1%) |
| Mar 2019 | - | -$81.44 M(+2.8%) | -$282.78 M(+3.2%) |
| Dec 2018 | -$274.14 M(-16.0%) | -$79.22 M(+42.3%) | -$274.14 M(-7.8%) |
| Sept 2018 | - | -$55.66 M(-16.3%) | -$297.41 M(-2.7%) |
| June 2018 | - | -$66.47 M(-8.7%) | -$305.62 M(-3.7%) |
| Mar 2018 | - | -$72.79 M(-29.0%) | -$317.37 M(-2.8%) |
| Dec 2017 | -$326.50 M | -$102.50 M(+60.5%) | -$326.50 M(-2.6%) |
| Sept 2017 | - | -$63.87 M(-18.3%) | -$335.26 M(-4.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2017 | - | -$78.21 M(-4.5%) | -$352.51 M(+0.5%) |
| Mar 2017 | - | -$81.92 M(-26.4%) | -$350.73 M(-11.2%) |
| Dec 2016 | -$394.80 M(+75.7%) | -$111.27 M(+37.2%) | -$394.80 M(+6.4%) |
| Sept 2016 | - | -$81.11 M(+6.1%) | -$371.16 M(+9.0%) |
| June 2016 | - | -$76.44 M(-39.3%) | -$340.53 M(+9.0%) |
| Mar 2016 | - | -$125.99 M(+43.8%) | -$312.52 M(+38.3%) |
| Dec 2015 | -$224.74 M(-20.5%) | -$87.62 M(+73.6%) | -$225.94 M(-34.2%) |
| Sept 2015 | - | -$50.48 M(+4.2%) | -$343.27 M(+4.4%) |
| June 2015 | - | -$48.43 M(+22.9%) | -$328.78 M(+33.2%) |
| Mar 2015 | - | -$39.41 M(-80.8%) | -$246.82 M(+8.8%) |
| Dec 2014 | -$282.78 M(+618.7%) | -$204.95 M(+469.4%) | -$226.88 M(+533.6%) |
| Sept 2014 | - | -$35.99 M(-207.3%) | -$35.81 M(+228.7%) |
| June 2014 | - | $33.54 M(-272.2%) | -$10.89 M(-79.1%) |
| Mar 2014 | - | -$19.48 M(+40.3%) | -$52.02 M(+32.2%) |
| Dec 2013 | -$39.35 M(+110.3%) | -$13.88 M(+25.3%) | -$39.35 M(+22.9%) |
| Sept 2013 | - | -$11.08 M(+46.0%) | -$32.01 M(+29.6%) |
| June 2013 | - | -$7.59 M(+11.6%) | -$24.69 M(+11.1%) |
| Mar 2013 | - | -$6.80 M(+4.0%) | -$22.23 M(+18.8%) |
| Dec 2012 | -$18.71 M(+39.4%) | -$6.54 M(+73.9%) | -$18.71 M(+13.3%) |
| Sept 2012 | - | -$3.76 M(-26.6%) | -$16.52 M(+5.7%) |
| June 2012 | - | -$5.12 M(+55.9%) | -$15.62 M(+48.8%) |
| Mar 2012 | - | -$3.29 M(-24.5%) | -$10.50 M(+45.5%) |
| Dec 2011 | -$13.42 M(-12.8%) | -$4.35 M(+51.8%) | -$7.22 M(+151.8%) |
| Sept 2011 | - | -$2.87 M | -$2.87 M |
| Dec 2010 | -$15.38 M | - | - |
FAQ
- What is Intercept Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Intercept Pharmaceuticals?
- What is Intercept Pharmaceuticals annual EBITDA year-on-year change?
- What is Intercept Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Intercept Pharmaceuticals?
- What is Intercept Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Intercept Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Intercept Pharmaceuticals?
- What is Intercept Pharmaceuticals TTM EBITDA year-on-year change?
What is Intercept Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ICPT is -$153.47 M
What is the all time high annual EBITDA for Intercept Pharmaceuticals?
Intercept Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$13.42 M
What is Intercept Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, ICPT annual earnings before interest, taxes, depreciation & amortization has changed by -$116.90 M (-319.63%)
What is Intercept Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ICPT is -$1.11 M
What is the all time high quarterly EBITDA for Intercept Pharmaceuticals?
Intercept Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $33.54 M
What is Intercept Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, ICPT quarterly earnings before interest, taxes, depreciation & amortization has changed by +$98.30 M (+98.88%)
What is Intercept Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ICPT is -$47.85 M
What is the all time high TTM EBITDA for Intercept Pharmaceuticals?
Intercept Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.87 M
What is Intercept Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, ICPT TTM earnings before interest, taxes, depreciation & amortization has changed by +$121.76 M (+71.79%)